EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing

Christian S Stevens, Jillian C Carmichael iD, Ruth Watkinson, Shreyas Kowdle, Rebecca A Reis iD, Kory Hamane, Jason Jang, Arnold Park iD, Olivier Pernet iD, Wannisa Khamaikawin, Patrick Hong, Patricia Thibault und 3 weitere

Journal of Virology · 2024

DOI: 10.1128/jvi.00832-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Christian S Stevens und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Gene Editing, Sendai virus, Receptors, CCR5, Hematopoietic Stem Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Molecular Biology Organization (EMBO), NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic potential of gene editing technologies hinges on the development of safe and effective delivery methods. In this study, we developed a temperature-sensitive and less immunogenic Sendai virus (ts SeV) as a novel delivery vector for CRISPR-Cas9 and for efficient gene editing in sensitive human cell types with limited induction of an innate immune response. ts SeV demonstrates high transduction efficiency in human CD34 + hematopoietic stem and progenitor cells (HSPCs) including transduction of the CD34 + /CD38 − /CD45RA − /CD90 + (Thy1 + )/CD49f high stem cell enriched subpopulation. The frequency of CCR5 editing exceeded 90% and bi-allelic CCR5 editing exceeded 70% resulting in significant inhibition of HIV-1 infection in primary human CD14 + monocytes. These results demonstrate the potential of the ts SeV platform as a safe, efficient, and flexible addition to the current gene-editing tool delivery methods, which may help further expand the possibilities in personalized medicine and the treatment of genetic disorders. IMPORTANCE Gene editing has the potential to be a powerful tool for the treatment of human diseases including HIV, β-thalassemias, and sickle cell disease. Recent advances have begun to overcome one of the major limiting factors of this technology, namely delivery of the CRISPR-Cas9 gene editing machinery, by utilizing viral vectors. However, gene editing therapies have yet to be implemented due to inherent risks associated with the DNA viral vectors typically used for delivery. As an alternative strategy, we have developed an RNA-based Sendai virus CRISPR-Cas9 delivery vector that does not integrate into the genome, is temperature sensitive, and does not induce a significant host interferon response. This recombinant SeV successfully delivered CRISPR-Cas9 in primary human CD14+ monocytes ex vivo resulting in a high level of CCR5 editing and inhibition of HIV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingSendai virusReceptors, CCR5Hematopoietic Stem CellsGenetic VectorsHumansCRISPR-Cas SystemsTemperatureHIV-1Transduction, GeneticHIV InfectionsMonocytes

Stichwörter der Autor:innen

CCR5CRISPR/Cas9HIVParamyxoviridaeSendai virusgene editinghematopoietic stem and progenitor cellsmonocytesviral vector

Substanzen

Receptors, CCR5CCR5 protein, human

Autor:innen und Institutionen

  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • UCLA School of Nursing, Los Angeles, California, USA.
  • UCLA AIDS Institute, Los Angeles, California, USA.

ORCID-Profile: Jillian C Carmichael, Rebecca A Reis, Arnold Park, Olivier Pernet, Dong Sung An, Benhur Lee

Förderung

  • European Molecular Biology Organization (EMBO)
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • HHS | National Institutes of Health (NIH)
  • Canadian Government | Canadian Institutes of Health Research (CIHR)

Zitieren

APA

Stevens, C. S., Carmichael, J. C., Watkinson, R., Kowdle, S., Reis, R. A., Hamane, K., Jang, J., Park, A., Pernet, O., Khamaikawin, W., Hong, P., Thibault, P., Gowlikar, A., An, D. S., & Lee, B. (2024). A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing. Journal of Virology. https://doi.org/10.1128/jvi.00832-24

Vancouver

Stevens CS, Carmichael JC, Watkinson R, Kowdle S, Reis RA, Hamane K, et al. A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing. Journal of Virology. 2024. doi:10.1128/jvi.00832-24

BibTeX
@article{Stevens2024,
  author = {Stevens, Christian S and Carmichael, Jillian C and Watkinson, Ruth and Kowdle, Shreyas and Reis, Rebecca A and Hamane, Kory and Jang, Jason and Park, Arnold and Pernet, Olivier and Khamaikawin, Wannisa and Hong, Patrick and Thibault, Patricia and Gowlikar, Aditya and An, Dong Sung and Lee, Benhur},
  title = {A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00832-24}
}
Kostenlos starten →